Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

@article{RomeroGmez2005InsulinRI,
  title={Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.},
  author={M. Romero-G{\'o}mez and Mar{\'i}a del Mar Viloria and R. Andrade and J. Salm{\'e}ron and M. Diago and C. Fern{\'a}ndez-Rodr{\'i}guez and R. Corpas and M. Cruz and L. Grande and Luis V{\'a}zquez and P. Mu{\~n}oz-de-Rueda and P. L{\'o}pez-Serrano and A. Gila and Mar{\'i}a L. Guti{\'e}rrez and C. P{\'e}rez and {\'A}. Ruiz-Extremera and E. Su{\'a}rez and J. Castillo},
  journal={Gastroenterology},
  year={2005},
  volume={128 3},
  pages={
          636-41
        }
}
BACKGROUND & AIMS We evaluated the effect of insulin resistance and viral factors on sustained virological response in patients with chronic hepatitis C treated with peginterferon plus ribavirin. METHODS Patients (n=159; 94 men; age, 41.7 +/- 11.1 years) with chronic hepatitis C (genotype 1, n=113; non-1 genotype, n=46) received treatment with interferon plus ribavirin. Serum levels of leptin and insulin were measured, and the insulin resistance index (HOMA-IR: homeostasis model of assessment… Expand
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.
TLDR
In patients with HCV genotype 1 infections, therapy with peginterferon and ribavirin is associated with decreases in body weight and insulin resistance, so HCV could have a direct role in the pathogenesis of insulin resistance. Expand
Insulin Resistance Predicts Rapid Virologic Response to Peginterferon/Ribavirin Combination Therapy in Hepatitis C Genotype 4 Patients
TLDR
IR is a major determinant of both RVR and SVR in genotype 4 CHC patients, and would seem to be a useful tool for predicting the response to therapy. Expand
Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV–hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study
TLDR
A high HOMA-IR level is frequently found in HIV-HCV-coinfected patients and is associated with a reduced SVR rate, suggesting improving insulin sensitivity might be a useful adjunct to HCV therapy in infected patients. Expand
Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.
TLDR
In patients with HCV genotype 1 infections, therapy with peginterferon and ribavirin is associated with decreases in body weight and insulin resistance, suggesting that HCV could have a direct role in the pathogenesis of insulin resistance. Expand
Insulin Resistance Impairs Response to Interferon Plus Ribavirin in Patients Coinfected With HIV and Hepatitis C Virus
TLDR
The data suggest that IR is an important determinant of SVR in HIV/HCV-coinfected patients treated with interferon plus ribavirin and strategies to modify IR should be explored to enhance SVR during anti-HCV therapy. Expand
Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients.
TLDR
Clinical application of pretreatment HOMA-IR could enable treatment outcome to be predicted and treatment regimens to be determined, especially among 'difficult-to-treat' patients. Expand
Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome.
  • G. Fattovich, G. S. Baroni, +8 authors F. Negro
  • Medicine
  • Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2012
TLDR
Insulin resistance, measured by both static and dynamic methods, does not predict rapid or sustained virologic response in chronic hepatitis C patients without the metabolic syndrome. Expand
Insulin resistance, viral load and response to peginterferon and ribavirin in patients with chronic hepatitis C virus infection
TLDR
It is concluded that insulin resistance (IR) is correlated independently with serum hepatitis C virus ( HCV)-RNA and frequently encountered in patients with HCV genotype 4 (HCV-4) infection. Expand
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naïve patients infected with HCV genotype 1
TLDR
It is suggested that metabolic factors and insulin resistance do not have a significant effect on telaprevir-based treatment efficacy and sustained virological response was associated with improved HOMA-IR. Expand
DOES INSULIN RESISTANCE IMPAIR THE VIROLOGICAL RESPONSE TO PEGINTERFERON/RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS?
TLDR
In this retrospective multicenter study of non-diabetic HCV genotype 3 positive patients, insulin resistance was not associated with the sustained virological response in patients who were treated with peginterferon/ribavirin. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C
TLDR
HLA class I B44 is related to a higher rate of SR in combination therapy but not in interferon monotherapy, whereas HLA class II, tumor necrosis factor-α −238A or −308A seem not to influence response to the antiviral therapy. Expand
Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.
TLDR
Black patients with chronic hepatitis C have a lower rate of response to treatment with peginterferon alfa-2b and ribavirin than non-Hispanic white patients, a difference that is not explained by differences in the viral genotype. Expand
High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C
TLDR
Obesity, only when defined as a BMI greater than 30 kg/m2, is an independent (of genotype and cirrhosis) negative predictor of response to hepatitis C treatment. Expand
Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C
TLDR
Serum triglyceride levels increase consistently in patients with chronic hepatitis C treated with all forms of α interferon, often to very high levels, although these changes do not seem to be associated with clinical signs or complications and triglycerides decline while patients are still on therapy and return to normal after stopping. Expand
Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C.
TLDR
In patients who were successfully treated with IFN-alpha, insulin sensitivity improved and their plasma glucose stayed at the same level without secreting as much insulin from islet beta-cells without developing autoantibodies. Expand
Interferon induces insulin resistance in patients with chronic active hepatitis C.
TLDR
It is indicated that interferon therapy for 2 weeks induces insulin resistance in the splanchnic, as well as peripheral tissues, in patients with chronic active hepatitis C, and more careful observation may be needed during interferons therapy in subjects with impaired glucose tolerance. Expand
Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression
TLDR
The hypothesis that insulin resistance may contribute to fibrotic progression in chronic hepatitis C virus infection is supported, and the effect seems to be genotype specific. Expand
The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.
TLDR
Steatosis is an important cofactor in hepatitis C as it is associated with fibrosis and reduces the likelihood of achieving early and sustained virologic response in genotype 1 infected patients. Expand
Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C
TLDR
It is concluded that the maintenance of a response to IFN in chronic hepatitis C may be, in part, determined by genetic factors in the host. Expand
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
TLDR
In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone. Expand
...
1
2
3
...